Last reviewed · How we verify
NCT06592157
Factors Influencing Wound Healing After Anal Fistula Surgery
trial testing NewEpi Plus Liquid Wound Dressing in Anal Fistula Surgery in 600 participants. Not yet recruiting.
30 June 2026
Quick facts
| Lead sponsor | Taichung Veterans General Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 10 September 2024 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
Drugs / interventions tested
- NewEpi Plus Liquid Wound Dressing
- standard wound care
Conditions studied
- Anal Fistula Surgery — all drugs for Anal Fistula Surgery →
Sponsor
Taichung Veterans General Hospital
Who can join
18 and older, any sex, with Anal Fistula Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this observational study is to analyze the factors influencing wound healing after anal fistula surgery and to assess the effectiveness of interventions in improving overall patient outcomes post-surgery. The primary questions this study aims to answer are: 1. Does the use of the growth factor (New Epi) contribute to accelerating wound healing, reducing the risk of infection, and enhancing patient recovery speed after surgery? 2. Do other factors, such as infection, nutritional status, diabetes, surgical methods, patient age and overall health, immune status, and lifestyle habits, affect the healing of surgical wounds?
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06592157
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anal Fistula Surgery
Currently open trials in the same condition.
- NCT07520500 — IFOC Compared With LIFT in High Anal Fistula · NA · recruiting
- NCT07477496 — Recurrence and Anal Fistula Patient Reported Outcomes Trial · recruiting
Other Taichung Veterans General Hospital trials
Trials by the same sponsor.
- NCT06858436 — SGLT2 Inhibitor Utilization Re-perfusion Therapy · Phase 4 · not yet recruiting
- NCT07453953 — A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis · EARLY_PHASE1 · not yet recruiting
- NCT07487636 — 4DryField PH and Head and Neck Operations. · NA · enrolling by invitation
- NCT07284017 — The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients. · NA · not yet recruiting
- NCT07363876 — The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06592157 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taichung Veterans General Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06592157.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing